MAPK3 and familial pancreatic carcinoma: As shown in Fig. 5A,B, ERK1/2 knockdown mimics the actions of metformin on gemcitabine-resistant pancreatic cancer cells that inhibiting cell proliferation and decreasing CD133+ cell proportion.